October 8, 2020

Canagliflozin (TA-7284) has been approvedin Indonesia for Type2 Diabetes Mellitus
Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President &Representative Director, CEO: Hiroaki Ueno), announced today that PT Mitsubishi
Tanabe Pharma Indonesia (MTID), MTPC’s subsidiary in Indonesia obtained theregulatory approval of CANAGLU® (generic name: canagliflozin hydrate; Japan
names: CANAGLU® Tablets 100mg) for a treatment agent for type 2 diabetes
mellitus from Indonesia FDA on September 18, 2020.
Canagliflozin is a treatment agent for type 2 diabetes mellitus discovered by MTPC
and was approved in Japan in July 2014. In 88 countries including the US andEurope, licensee Janssen Pharmaceuticals, Inc. has received approval of
Canagliflozin under the brand name INVOKANAIn Indonesia, the number of patients with type 2 diabetes has been increasing inrecent years, and it is estimated that this trend will continue. MTID was establishedin July 1970 and has supplied numerous products for lifestyle-related diseases inIndonesia for 50 years. MTID will utilize the business foundation it has built throughthe sale of these products, and with the sale of CANAGLU® as an opportunity, willcontribute to the treatment of patients with type 2 diabetes in Indonesia.
By providing a new option for the treatment of diabetes to a growing number ofpatients in the world, MTPC shows its continued resolve to improve their quality oflife (QOL).

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119

1/2

<Reference>■canagliflozin (Japan names: CANAGLU® Tablets 100mg)
Canagliflozin (generic name: canagliflozin hydrate; Japan names: CANAGLU®
Tablets 100mg) is an SGLT2 inhibitor that originated in Japan. It is a treatment fortype 2 diabetes mellitus which was discovered by Mitsubishi Tanabe Pharma andhas its research roots in T-1095, the world’s first orally bioavailable sodium glucose
co-transporter inhibitor. CANAGLU® inhibits SGLT2, a transporter involved in thereabsorption of glucose in the renal tubules of the kidneys, suppresses thereabsorption of glucose, promotes the excretion of excessive glucose into the urine,and as a result, lowers the blood glucose level. Canagliflozin was approved in Japan,
July 20154 followed by Taiwan in March 2017.
More than 11,000 patients with type 2 diabetes were enrolled in global Phase 3
programs, including in Japan, which assessed the efficacy and safety of CANAGLU®.
The development program included a mono-therapy, dual and triple combination
therapies with other anti-hyperglycemic agents and also involved type 2 diabetes
patients with impaired renal function, patients who have or are at high risk ofdeveloping cardiovascular diseases and elderly patients.

■PT Mitsubishi Tanabe Pharma Indonesia
PT Mitsubishi Tanabe Pharma Indonesia (MTID) was established in July 1970 and is
manufacturing and sales subsidiary of MTPC. Its Headquarters is in Jakarta, sales
bases in 13 locations throughout Indonesia, and production bases in Bandung inIndonesia.
MTID has been operating in Indonesia for 50 years and has marketed a number oflifestyle-related disease products including Herbesser®, Tanapress® (Japan name:Tanatril®) and LIVALO®. MTID will utilize the business foundation establishedthrough the sales of these products, and through the sales of CANAGLU® willcontribute to the treatment of patients with type 2 diabetes in Indonesia. In addition
to the ASEAN countries, MTID supplies products to Hong Kong, Sri Lanka, Brazil,Pakistan, and other countries. With the objective of increasing production capacityand further improving quality, MTID constructed a new formulation building inBandung, which began operating in January 2015.

2/2